首页> 外文期刊>Indian Journal of Experimental Biology >Assessment of protective role of polyherbal preparation, Livina, against anti-tubercular drug induced liver dysfunction
【24h】

Assessment of protective role of polyherbal preparation, Livina, against anti-tubercular drug induced liver dysfunction

机译:评估多草药制剂Livina对抗结核药性肝功能障碍的保护作用

获取原文
获取原文并翻译 | 示例
           

摘要

The present study evaluated the possible protective role of Livina (a polyherbal preparation) against anti-tubercular therapy (ATT)-induced liver dysfunction in patients of pulmonary tuberculosis. Patients were given intensive phase treatment with 4-drugs (rifampicin, INH, pyrazinamide and ethambutol) used for anti-tubercular therapy for 2 months, followed by a 4-month continuous phase treatment with 2 drugs (rifampicin and INH) under clinical advice and supervision. Both qualitative and quantitative measures of liver function were assessed, at different time intervals, before and after ATT. Analysis of data showed that the incidence of qualitative manifestations of liver dysfunction were greater in the placebo treated group as compared to the test drug group. None of the patients of either group showed clinical jaundice. Most signific changes ant were observed in the SGOT and SGPT levels in the placebo group, wherein the levels of both enzymes were higher at 4 and 8 weeks post-ATT, as compared to the respective baseline (0 week) values. When Livina (2 capsules twice daily) was given with ATT drugs, incidence of qualitative manifestation of liver dysfunction was insignificant and SGOT and SGPT levels were also significantly lower than the placebo+ATT drugs treated group. These results indicate that the test drug (Livina) was efficacious, against ATT-induced hepatic dysfunction in patients of pulmonary tuberculosis.
机译:本研究评估了利维那(一种多草药制剂)对肺结核患者抗结核治疗(ATT)引起的肝功能障碍的可能的保护作用。患者接受4种药物(利福平,INH,吡嗪酰胺和乙胺丁醇)的强化阶段治疗,用于抗结核治疗2个月,然后在临床建议和指导下用2种药物(利福平和INH)进行为期4个月的连续阶段治疗。监督。在ATT之前和之后的不同时间间隔,对肝功能的定性和定量指标进行了评估。数据分析表明,与试验药物组相比,安慰剂治疗组的肝功能异常定性表现的发生率更高。两组患者均未出现临床黄疸。安慰剂组在SGOT和SGPT水平上观察到了最显着的变化,其中ATT后4周和8周的两种酶的水平均高于各自的基线(0周)值。当Livina(每天2次,每次2粒胶囊)与ATT药物合用时,肝功能障碍的定性表现发生率不高,并且SGOT和SGPT水平也显着低于安慰剂+ ATT药物治疗组。这些结果表明,测试药物(Livina)对肺结核患者由ATT引起的肝功能障碍有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号